Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model

[1]  P. Desai,et al.  Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module , 2015, Drug Delivery and Translational Research.

[2]  F. Zahedifard,et al.  Assessment of Protection Induced by DNA and Live Vaccine Encoding Leishmania MHC Class I Restricted Epitopes against L. major Challenge in Balb/c Mice Model , 2015 .

[3]  S. Rafati,et al.  Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica , 2015, AAPS PharmSciTech.

[4]  A. Amaral,et al.  Natural Products: Insights into Leishmaniasis Inflammatory Response , 2015, Mediators of inflammation.

[5]  J. Pereira,et al.  Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[6]  O. Sammour,et al.  Recent advances in topical formulation carriers of antifungal agents. , 2015, Indian journal of dermatology, venereology and leprology.

[7]  A. Ganem-Rondero,et al.  Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Occlusive Effect and Penetration Enhancement Ability , 2015 .

[8]  N. Seyed,et al.  Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity. , 2015, Experimental parasitology.

[9]  A. Hemmati,et al.  Effect of topical Nanoliposomes of Paromomycin on Rats Liver and Kidney , 2014, Jundishapur journal of natural pharmaceutical products.

[10]  M. K. Chourasia,et al.  Chitosan-Assisted Immunotherapy for Intervention of Experimental Leishmaniasis via Amphotericin B-Loaded Solid Lipid Nanoparticles , 2014, Applied Biochemistry and Biotechnology.

[11]  R. López-Vélez,et al.  Topical Paromomycin and Gentamicin for New World Cutaneous Leishmaniasis in Panama , 2014, The American journal of tropical medicine and hygiene.

[12]  S. Meehan,et al.  New world cutaneous leishmaniasis. , 2012, Dermatology online journal.

[13]  Hao Peng,et al.  The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. , 2013, Materials science & engineering. C, Materials for biological applications.

[14]  M. Grogl,et al.  Pharmacokinetics and Absorption of Paromomycin and Gentamicin from Topical Creams Used To Treat Cutaneous Leishmaniasis , 2013, Antimicrobial Agents and Chemotherapy.

[15]  Neeraj Kumar,et al.  Bioanalytical method development, pharmacokinetics, and toxicity studies of paromomycin and paromomycin loaded in albumin microspheres. , 2013, Drug testing and analysis.

[16]  M. Mohebali,et al.  Cutaneous and post kala-azar dermal leishmaniasis caused by Leishmania infantum in endemic areas of visceral leishmaniasis, northwestern Iran 2002–2011: a case series , 2013, Pathogens and global health.

[17]  Mara Kreishman-Deitrick,et al.  Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. , 2013, The New England journal of medicine.

[18]  Nisha Singh,et al.  Leishmaniasis: current status of available drugs and new potential drug targets. , 2012, Asian Pacific journal of tropical medicine.

[19]  S. Fatemi,et al.  Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. , 2012, International journal of pharmaceutics.

[20]  A. H. Sathali,et al.  SOLID LIPID NANOPARTICLES: A REVIEW , 2017 .

[21]  M. Ghadiri,et al.  Paromomycin loaded solid lipid nanoparticles: Characterization of production parameters , 2011 .

[22]  F. Zahedifard,et al.  Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[23]  P. Shelat,et al.  Nanoemulsion: A pharmaceutical review , 2010 .

[24]  E. A. Nunan,et al.  Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis , 2009, Journal of liposome research.

[25]  P. Pescher,et al.  Leishmania major MPK7 Protein Kinase Activity Inhibits Intracellular Growth of the Pathogenic Amastigote Stage , 2009, Eukaryotic Cell.

[26]  A. Khamesipour,et al.  Effect of Topical Liposomes Containing Paromomycin Sulfate in the Course of Leishmania major Infection in Susceptible BALB/c Mice , 2009, Antimicrobial Agents and Chemotherapy.

[27]  Rainer H Müller,et al.  Lipid nanoparticles for parenteral delivery of actives. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[28]  D. Kim,et al.  Is Paromomycin an Effective and Safe Treatment against Cutaneous Leishmaniasis? A Meta-Analysis of 14 Randomized Controlled Trials , 2009, PLoS neglected tropical diseases.

[29]  A. Kiderlen,et al.  Intracellular parasite kill: flow cytometry and NO detection for rapid discrimination between anti-leishmanial activity and macrophage activation. , 2008, Journal of immunological methods.

[30]  M. Joshi,et al.  Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. , 2007, Advanced drug delivery reviews.

[31]  W. Tiyaboonchai,et al.  Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. , 2007, International journal of pharmaceutics.

[32]  S. Croft,et al.  Chemotherapy in the treatment and control of leishmaniasis. , 2006, Advances in parasitology.

[33]  Si-Shen Feng,et al.  Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[34]  R. Pearson,et al.  Immunopathogenesis of infection with the visceralizing Leishmania species. , 2005, Microbial pathogenesis.

[35]  V. Venkateswarlu,et al.  Solid lipid nanoparticles as drug delivery systems. , 2005, Methods and findings in experimental and clinical pharmacology.

[36]  S. Sundar,et al.  Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  E. A. Nunan,et al.  In Vitro Skin Permeation and Retention of Paromomycin from Liposomes for Topical Treatment of the Cutaneous Leishmaniasis , 2004, Drug development and industrial pharmacy.

[38]  Rainer H. Müller,et al.  Cytotoxicity of Solid Lipid Nanoparticles as a Function of the Lipid Matrix and the Surfactant , 1997, Pharmaceutical Research.

[39]  S. Croft,et al.  Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. , 2003, Trends in parasitology.

[40]  H. Murray,et al.  Immunoenhancement Combined with Amphotericin B as Treatment for Experimental Visceral Leishmaniasis , 2003, Antimicrobial Agents and Chemotherapy.

[41]  P. Desjeux.  The increase in risk factors for leishmaniasis worldwide. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[42]  A. Satoskar,et al.  Endogenous IL‐4 is necessary for effective drug therapy against visceral leishmaniasis , 2000, European journal of immunology.

[43]  A. Sönnerborg,et al.  HIV viral load and response to antileishmanial chemotherapy in co-infected patients. , 1999, AIDS.

[44]  R. López-Vélez,et al.  Leishmania and human immunodeficiency virus coinfection: the first 10 years , 1997, Clinical microbiology reviews.

[45]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization , 1994 .

[46]  T. Evans,et al.  Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. , 1993, Journal of immunology.

[47]  S. Reed,et al.  New perspectives on a subclinical form of visceral leishmaniasis. , 1986, The Journal of infectious diseases.

[48]  D. Heyneman.  Immunology of leishmaniasis. , 1971, Bulletin of the World Health Organization.